Literature DB >> 30559321

The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.

Wenbin Ma1,2,3, Vincent Stroobant1,2,3, Carlo Heirman4, Zhaojun Sun1,3, Kris Thielemans4, Arend Mulder5, Pierre van der Bruggen1,2,3, Benoît J Van den Eynde6,2,3.   

Abstract

The intracellular pathway of cross-presentation, which allows MHC class I-restricted presentation of peptides derived from exogenous Ags, remains poorly defined and may vary with the nature of the exogenous Ag and the type of APC. It can be cytosolic, characterized by proteasome and TAP dependency, or vacuolar, usually believed to be proteasome and TAP independent. Cross-presentation is particularly effective with long synthetic peptides, and we previously reported that the HLA-A2-restricted cross-presentation of a long peptide derived from melanoma Ag gp100 by human monocyte-derived immature dendritic cells occurred in a vacuolar pathway, making use of newly synthesized HLA-A2 molecules that follow a nonclassical secretion route. In this article, we show that the HLA-A1-restricted cross-presentation of a long peptide derived from tumor Ag MAGE-A3 by human monocyte-derived immature dendritic cells also follows a vacuolar pathway. However, as opposed to the HLA-A2-restricted peptide, cross-presentation of the HLA-A1-restricted peptide is TAP dependent. We show that this paradoxical TAP-dependency is indirect and reflects the need for TAP to load HLA-A1 molecules with peptides in the endoplasmic reticulum, to allow them to escape the endoplasmic reticulum and reach the vacuole, where peptide exchange with the cross-presented peptide likely occurs. Our results confirm and extend the involvement of the vacuolar pathway in the cross-presentation of long peptides, and indicate that TAP-dependency can no longer be used as a key criterion to distinguish the cytosolic from the vacuolar pathway of cross-presentation. They also stress the existence of an alternative secretory route for MHC class I, which will be worthy of further studies.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30559321     DOI: 10.4049/jimmunol.1800353

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Authors:  Ian Mantel; Barzan A Sadiq; J Magarian Blander
Journal:  Mol Immunol       Date:  2021-12-29       Impact factor: 4.174

Review 2.  Cross-presentation of exogenous antigens on MHC I molecules.

Authors:  Jeff D Colbert; Freidrich M Cruz; Kenneth L Rock
Journal:  Curr Opin Immunol       Date:  2020-01-09       Impact factor: 7.486

3.  The role of MHC class I recycling and Arf6 in cross-presentation by murine dendritic cells.

Authors:  Sebastian Montealegre; Anastasia Abramova; Valerie Manceau; Anne-Floor de Kanter; Peter van Endert
Journal:  Life Sci Alliance       Date:  2019-11-18

Review 4.  Vaccine-Induced CD8+ T Cell Responses in Children: A Review of Age-Specific Molecular Determinants Contributing to Antigen Cross-Presentation.

Authors:  Elisabeth M S Beijnen; Simon D van Haren
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

Review 5.  The Ubiquitin-Proteasome System in Immune Cells.

Authors:  Gonca Çetin; Sandro Klafack; Maja Studencka-Turski; Elke Krüger; Frédéric Ebstein
Journal:  Biomolecules       Date:  2021-01-05

6.  Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Authors:  Yanling Xiao; Harry Dolstra; Willemijn Hobo; Jesper van Eck van der Sluijs; Diede van Ens; Soley Thordardottir; Denise Vodegel; Inge Hermens; Anniek B van der Waart; J H Frederik Falkenburg; Michel G D Kester; Iris de Rink; Mirjam H M Heemskerk; Jannie Borst; Nicolaas P M Schaap; Joop H Jansen
Journal:  Cancer Immunol Immunother       Date:  2021-04-01       Impact factor: 6.968

7.  Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.

Authors:  Lukas Jac Hawinkels; Els Me Verdegaal; Tom J Harryvan; Marten Visser; Linda de Bruin; Léonie Plug; Lisa Griffioen; Arend Mulder; Peter A van Veelen; Gerbrand J van der Heden van Noort; Marlieke Lm Jongsma; Miranda H Meeuwsen; Emmanuel Jhj Wiertz; Saskia J Santegoets; James Ch Hardwick; Thorbald Van Hall; Jacques Neefjes; Sjoerd H Van der Burg
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

8.  Nanoscale organization of the MHC I peptide-loading complex in human dendritic cells.

Authors:  Nicole Koller; Philipp Höllthaler; Martina Barends; Marius Döring; Christoph Spahn; Verónica Durán; Bibiana Costa; Jennifer Becker; Mike Heilemann; Ulrich Kalinke; Robert Tampé
Journal:  Cell Mol Life Sci       Date:  2022-08-10       Impact factor: 9.207

Review 9.  Vaccine adjuvants to engage the cross-presentation pathway.

Authors:  Woojong Lee; M Suresh
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

Review 10.  Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.

Authors:  Xiaotong Chen; Ju Yang; Lifeng Wang; Baorui Liu
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.